Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 01.04.2024 1 AIDS 1 Ann Intern Med 1 BMJ 1 Clin Infect Dis 1 J Gen Virol 2 J Infect Dis 3 J Virol 1 JAMA 1 Lancet 1 MMWR Morb Mortal Wkly Rep 2 Nat Med 1 Pediatr Infect Dis J 2 Pediatrics 4 PLoS One 2 Science 18 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. GIANELLA S, Anderson C, Chaillon A, Wells A, et al
   Impact of influenza and pneumococcal vaccines on HIV persistence and immune dynamics during suppressive antiretroviral therapy.
   AIDS. 2024 Mar 25. doi: 10.1097/QAD.0000000000003882.
   PubMed         Abstract available
   
   

   
   Ann Intern Med

2. WELLS CR, Pandey A, Moghadas SM, Fitzpatrick MC, et al
   Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
   Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-2451.
   PubMed         Abstract available
   
   

   
   BMJ

3. MAHASE E
   Covid-19: Pfizer vaccine to be available privately at pharmacy chain Boots from April.
   BMJ. 2024;384:q762.
   PubMed        
   
   

   
   Clin Infect Dis

4. ROSTAD CA, Atmar RL, Walter EB, Frey S, et al
   A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US
   Clin Infect Dis. 2024 Mar 27:ciae173. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Gen Virol

5. SAMOLEJ J, White IJ, Strang BL, Mercer J, et al
   Cardiac glycosides inhibit early and late vaccinia virus protein expression.
   J Gen Virol. 2024;105.
   PubMed         Abstract available
   
   

   
   J Infect Dis

6. KAO CM, Rostad CA, Nolan LE, Peters E, et al
   A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
   J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093.
   PubMed         Abstract available
   
   
7. KALIZANG'OMA A, Swarthout TD, Mwalukomo TS, Kamng'ona A, et al
   Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.
   J Infect Dis. 2024 Mar 26:jiae040. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

8. WU K, Hou YJ, Makrinos D, Liu R, et al
   Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
   J Virol. 2024 Mar 25:e0160323. doi: 10.1128/jvi.01603.
   PubMed         Abstract available
   
   
9. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
   A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
   J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
   PubMed         Abstract available
   
   
10. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
    Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
    J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
    PubMed         Abstract available
    
    

    
    JAMA

11. HARRIS E
    WHO Issues First Recommendations for Managing Diphtheria.
    JAMA. 2024;331:907.
    PubMed        
    
    

    
    Lancet

12. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

13. LINK-GELLES R, Rowley EAK, DeSilva MB, Dascomb K, et al
    Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged >/=18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:271-276.
    PubMed         Abstract available
    
    

    
    Nat Med

14. O'LEARY K
    Going the extra mile to increase vaccine uptake.
    Nat Med. 2024 Mar 28. doi: 10.1038/d41591-024-00022.
    PubMed        
    
    
15. RAPPAPORT AR, Kyi C, Lane M, Hart MG, et al
    A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Nat Med. 2024 Mar 27. doi: 10.1038/s41591-024-02851.
    PubMed         Abstract available
    
    

    
    Pediatr Infect Dis J

16. SENDERS S, Klein NP, Tamimi N, Thompson A, et al
    A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Pediatr Infect Dis J. 2024 Mar 26. doi: 10.1097/INF.0000000000004334.
    PubMed         Abstract available
    
    

    
    Pediatrics

17. DALAPATI T, Williams CA, Giorgi EE, Hurst JH, et al
    Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children Less Than 5 Years of Age.
    Pediatrics. 2024 Mar 29. doi: 10.1542/peds.2024-066190.
    PubMed         Abstract available
    
    
18. GAVIRIA-AGUDELO C, Yonts AB, Kimberlin DW, Campbell JD, et al
    February 2024 ACIP Meeting Update: Meningococcal, RSV, COVID-19, and Other Vaccines.
    Pediatrics. 2024 Mar 29. doi: 10.1542/peds.2024-066653.
    PubMed         Abstract available
    
    

    
    PLoS One

19. PAUDEL S, Apostolakos I, Vougat Ngom R, Tilli G, et al
    A systematic review and meta-analysis on the efficacy of vaccination against colibacillosis in broiler production.
    PLoS One. 2024;19:e0301029.
    PubMed         Abstract available
    
    
20. DIMNJAKOVIC J, Buble T, Ivanko P, Poljicanin T, et al
    Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis.
    PLoS One. 2024;19:e0301056.
    PubMed         Abstract available
    
    
21. BRAY LA, Jervis LL, Janitz AE, Ross L, et al
    Toward trustworthy COVID-19 interventions: Building vaccine trust through community-university partnerships.
    PLoS One. 2024;19:e0300872.
    PubMed         Abstract available
    
    
22. AZAMAR-LLAMAS D, Arenas-Martinez JS, Olivas-Martinez A, Jimenez JV, et al
    Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico.
    PLoS One. 2024;19:e0301198.
    PubMed         Abstract available
    
    

    
    Science

23. MICHEL AL
    Vaccines to control tuberculosis in cattle.
    Science. 2024;383:1410-1411.
    PubMed         Abstract available
    
    
24. FROMSA A, Willgert K, Srinivasan S, Mekonnen G, et al
    BCG vaccination reduces bovine tuberculosis transmission, improving prospects for elimination.
    Science. 2024;383:eadl3962.
    PubMed         Abstract available
    
    

    
    Vaccine

25. FUKUDA Y, Suzuki T, Iwata KI, Haruta K, et al
    Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus.
    Vaccine. 2024 Mar 27:S0264-410X(24)00333-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
26. BRUUN N, Laursen MF, Carmelo R, Christensen E, et al
    Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo.
    Vaccine. 2024 Mar 26:S0264-410X(24)00364-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
27. ZHAO Z, Meng Q, Sun TZ, Zhu B, et al
    Mannose modified targeted immersion vaccine delivery system improves protective immunity against Infectious spleen and kidney necrosis virus in mandarin fish (Siniperca chuatsi).
    Vaccine. 2024 Mar 21:S0264-410X(24)00335-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
28. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
29. ZHANG Y, Wang Y, Li G, Zhao X, et al
    A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older.
    Vaccine. 2024 Mar 21:S0264-410X(24)00331-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
30. HIRTH J, Ostovar-Kermani T, Gutierrez JA, Thompson EL, et al
    Effect of age at initiation of the human papillomavirus vaccine on the association between race/ethnicity and completion of the vaccine series.
    Vaccine. 2024 Mar 21:S0264-410X(24)00336-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
31. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
32. COMES JDG, Doets K, Zegers T, Kessler M, et al
    Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
    Vaccine. 2024 Mar 22:S0264-410X(24)00319-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
33. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. STUREBORG R, Nichols J, Dhingra B, Yang J, et al
    Development and validation of VaxConcerns: A taxonomy of vaccine concerns and misinformation with Crowdsource-Viability.
    Vaccine. 2024 Mar 22:S0264-410X(24)00255-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. PONNE S, Kumar R, Vanmathi SM, Brilhante RSN, et al
    Reverse engineering protection: A comprehensive survey of reverse vaccinology-based vaccines targeting viral pathogens.
    Vaccine. 2024 Mar 23:S0264-410X(24)00265-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
37. DAHL BA, Tritter B, Butryn D, Dahlke M, et al
    Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
    Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
38. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
39. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
40. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
41. WEYANT C, Hooda Y, Munira SJ, Lo NC, et al
    Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.
    Vaccine. 2024 Mar 25:S0264-410X(24)00322-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
42. PARISI A, Nunez O, Lopez-Perea N, Masa-Calles J, et al
    Reduced pertussis disease severity in infants following the introduction of pertussis vaccination of pregnant women in Spain, 2015-2019.
    Vaccine. 2024 Mar 25:S0264-410X(24)00315-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.